Literature DB >> 17332438

AMP-activated protein kinase in the heart: role during health and disease.

Michael Arad1, Christine E Seidman, J G Seidman.   

Abstract

AMP-activated protein kinase (AMPK) is a heterotrimeric enzyme that is expressed in most mammalian tissues including cardiac muscle. Among the multiple biological processes influenced by AMPK, regulation of fuel supply and energy-generating pathways in response to the metabolic needs of the organism is fundamental and likely accounts for the remarkable evolutionary conservation of this enzyme complex. By regulating the activity of acetyl-coenzyme A carboxylase, AMPK affects levels of malonyl-coenzyme A, a key energy regulator in the cell. AMPK is generally quiescent under normal conditions but is activated in response to hormonal signals and stresses sufficient to produce an increase in AMP/ATP ratio, such as hypoglycemia, strenuous exercise, anoxia, and ischemia. Once active, muscle AMPK enhances uptake and oxidative metabolism of fatty acids as well as increases glucose transport and glycolysis. Data from AMPK deficiency models suggest that AMPK activity might influence the pathophysiology and therapy of diabetes and increase heart tolerance to ischemia. Effects that are not as well understood include AMPK regulation of transcription. Different AMPK isoforms are found in distinct locations within the cell and have distinct functions in different tissues. A principal mode of AMPK activation is phosphorylation by upstream kinases (eg, LKB1). These kinases have a fundamental role in cell-cycle regulation and protein synthesis, suggesting involvement in a number of human disorders including cardiac hypertrophy, apoptosis, cancer, and atherosclerosis. The physiological role played by AMPK during health and disease is far from being clearly defined. Naturally occurring mutations affecting the nucleotide-sensing modules in the regulatory gamma subunit of AMPK lead to enzyme dysregulation and inappropriate activation under resting conditions. Glycogen accumulation ensues, leading to human disease manifesting as cardiac hypertrophy, accessory atrioventricular connections, and degeneration of the physiological conduction system. Whether AMPK is a key participant or bystander in other disease states and whether its selective manipulation may significantly benefit these conditions remain important questions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17332438     DOI: 10.1161/01.RES.0000258446.23525.37

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  130 in total

1.  AMP-activated protein kinase phosphorylates cardiac troponin I at Ser-150 to increase myofilament calcium sensitivity and blunt PKA-dependent function.

Authors:  Benjamin R Nixon; Ariyoporn Thawornkaiwong; Janel Jin; Elizabeth A Brundage; Sean C Little; Jonathan P Davis; R John Solaro; Brandon J Biesiadecki
Journal:  J Biol Chem       Date:  2012-04-06       Impact factor: 5.157

2.  AMPK protects proximal tubular cells from stress-induced apoptosis by an ATP-independent mechanism: potential role of Akt activation.

Authors:  Wilfred Lieberthal; Leiqing Zhang; Vimal A Patel; Jerrold S Levine
Journal:  Am J Physiol Renal Physiol       Date:  2011-09-28

3.  Effects of high-mobility group box 1 on the expression of Beclin-1 and LC3 proteins following hypoxia and reoxygenation injury in rat cardiomyocytes.

Authors:  Weipan Xu; Hong Jiang; Xiaorong Hu; Wenwen Fu
Journal:  Int J Clin Exp Med       Date:  2014-12-15

4.  Effects of the AMP-activated protein kinase inhibitor compound C on the postconditioned rat heart.

Authors:  R Hermann; M G Marina Prendes; M E Torresin; D Vélez; E A Savino; A Varela
Journal:  J Physiol Sci       Date:  2012-05-22       Impact factor: 2.781

5.  AMP-activated protein kinase deficiency exacerbates aging-induced myocardial contractile dysfunction.

Authors:  Subat Turdi; Xiujuan Fan; Ji Li; Junxing Zhao; Anna F Huff; Min Du; Jun Ren
Journal:  Aging Cell       Date:  2010-05-10       Impact factor: 9.304

Review 6.  Regulation of AMPK by the ubiquitin proteasome system.

Authors:  Makhosazane Zungu; Jonathan C Schisler; M Faadiel Essop; Chris McCudden; Cam Patterson; Monte S Willis
Journal:  Am J Pathol       Date:  2010-12-23       Impact factor: 4.307

7.  Navigational error in the heart leads to premature ventricular excitation.

Authors:  Hiroshi Akazawa; Issei Komuro
Journal:  J Clin Invest       Date:  2011-01-25       Impact factor: 14.808

Review 8.  Autophagy in ischemic heart disease.

Authors:  Asa B Gustafsson; Roberta A Gottlieb
Journal:  Circ Res       Date:  2009-01-30       Impact factor: 17.367

9.  Severe hypertrophic cardiomyopathy in an infant with a novel PRKAG2 gene mutation: potential differences between infantile and adult onset presentation.

Authors:  Brendan P Kelly; Mark W Russell; James R Hennessy; Gregory J Ensing
Journal:  Pediatr Cardiol       Date:  2009-11       Impact factor: 1.655

10.  Reversibility of PRKAG2 glycogen-storage cardiomyopathy and electrophysiological manifestations.

Authors:  Cordula M Wolf; Michael Arad; Ferhaan Ahmad; Atsushi Sanbe; Scott A Bernstein; Okan Toka; Tetsuo Konno; Gregory Morley; Jeffrey Robbins; J G Seidman; Christine E Seidman; Charles I Berul
Journal:  Circulation       Date:  2007-12-24       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.